Over time, molecular biology and genomics techniques have been developed to speed up
the early diagnosis and clinical management of cancer. These therapies are often most …

Over time, molecular biology and genomics techniques have been developed to speed up
the early diagnosis and clinical management of cancer. These therapies are often most …

Recent advancements in molecular diagnostics have highlighted the potential of circulating
cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the …

Translational research of liquid biopsy is just at the edge of routine clinical application: an
emerging validity of circulating tumor DNA (ctDNA) tests suggests its use for earlier cancer …

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

Liquid biopsies are a valuable non-invasive biomarker source for the diagnosis, prognosis
and monitoring of cancer patients. The detection of circulating cell-free DNA (cfDNA) derived …

There is a strong demand for the identification of new biomarkers in colorectal cancer (CRC)
diagnosis. Among all liquid biopsy analysts, cell-free circulating DNA (cfDNA) is probably …

The incidence and mortality of colorectal cancer (CRC) are considerably high in Central
European countries, it is the second most common cancer in both men and women in …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

As we conclude this Special Issue of 21 published articles dedicated to cell-free DNA
(cfDNA) as a prognostic and predictive biomarker in solid cancers, we find ourselves gazing …